Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck profit tops estimates on strong diabetes, cancer drug sales

10/27/2015 | 09:57am EDT

(Reuters) - Merck & Co Inc (>> Merck & Co., Inc.) on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.

(Reuters) - Merck & Co Inc (>> Merck & Co., Inc.) on Tuesday reported a higher-than-expected quarterly profit and raised its full-year forecast as demand for its diabetes and cancer drugs increased.

Combined sales of diabetes drug Januvia and a related pill called Janumet, which have struggled to grow in the past year, jumped 10 percent to $1.58 billion in the third quarter after only a 1 percent rise in the previous period.

Adam Schechter, Merck's head of global human health, said in a conference call with analysts that the treatments for type 2 diabetes got a $100 million boost from stocking by wholesalers. But he cautioned that the gain would hamper their sales in the fourth quarter and beyond.

Schechter said the volume of Januvia sales rose 4 percent in the quarter, which he called an encouraging trend.

Keytruda, the company's new advanced melanoma and lung cancer treatment from a promising class of immuno-oncology drugs, brought in sales of $159 million.

"Merck continues to execute well in oncology with Keytruda," BMO Capital Markets analyst Alex Arfaei said in a research note. He predicted the drug, which blocks a protein called PD-1 that allows tumors to hide from the immune system, would achieve annual sales of about $9 billion by 2023 as a treatment for multiple types of cancer.

Merck Chief Executive Officer Ken Frazier said negative media reports about Valeant Pharmaceuticals International (>> Valeant Pharmaceuticals Intl Inc) (>> Valeant Pharmaceuticals Intl Inc) and other companies that have dramatically raised prices of their prescription drugs had created "a lot of noise" without seriously tarnishing the industry's reputation.

"People recognize the industry is important," Frazier said on the conference call. "Our innovations are critical to society."

Merck, whose shares were up 1.2 percent in morning trading, said its net income doubled to $1.83 billion, or 64 cents per share, from $895 million, or 31 cents per share, a year earlier.

Excluding special items, including restructuring and acquisitions, earnings of 96 cents per share exceeded the analysts' average estimate of 91 cents, according to Thomson Reuters I/B/E/S.

Revenue fell 5 percent to $10.07 billion, slightly below Wall Street forecasts of $10.08 billion.

Excluding the impact of a strong dollar and other factors, revenue would have risen 4 percent, Merck said.

Merck raised its 2015 profit forecast to a range of $3.55 to $3.60 per share. It had previously expected $3.45 to $3.55.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)


ę Reuters 2015
Stocks mentioned in the article
ChangeLast1st jan.
LABORATORY CORPORATION OF AMERICA HOLDINGS 0.00% 300.08 Delayed Quote.47.42%
MERCK & CO., INC. -1.22% 75.48 Delayed Quote.-7.73%
All news about MERCK & CO., INC.
07/30MERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintain..
MT
07/30MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Ma..
MT
07/29SECTOR UPDATE : Health Care Stocks Closing Slightly Higher
MT
07/29SECTOR UPDATE : Health Care Stocks Inching Higher This Afternoon
MT
07/29MERCK : weighed down by charges in Q2, but drug sales rebound
AQ
07/29MERCK : Announces Appointment of Cristal N. Downing as Chief Communications & Pu..
BU
07/29Merck & Co., Inc. Announces Appointment of Cristal N. Downing as Chief Commun..
CI
07/29MERCK : Reports Higher Second-Quarter Results But Mixed Against Street Views, Na..
MT
07/29SECTOR UPDATE : Health Care Stocks Cautiously Up Ahead of Thursday's Opening Bel..
MT
07/29Today on Wall Street: GDP growth misses estimates
More news
Financials (USD)
Sales 2021 46 932 M - -
Net income 2021 12 744 M - -
Net Debt 2021 12 127 M - -
P/E ratio 2021 17,1x
Yield 2021 3,42%
Capitalization 191 B 191 B -
EV / Sales 2021 4,33x
EV / Sales 2022 3,93x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 75,48 $
Average target price 94,45 $
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-7.73%191 120
JOHNSON & JOHNSON10.15%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.22.77%255 703
ELI LILLY AND COMPANY55.45%232 701
NOVARTIS AG-0.20%224 638